Orlistat

Drug Profile

Orlistat

Alternative Names: alli; Orlipastat; R 212; RO 180647; Tetrahydrolipstatin; Xenical; Zenical

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Roche
  • Class Anorectics; Lactones
  • Mechanism of Action Lipase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Obesity

Most Recent Events

  • 06 Dec 2012 Invida is now called Menarini Asia-Pacific
  • 09 Dec 2011 First generic equivalent available in the UK for obesity
  • 11 Nov 2011 Invida Group has been acquired by Menarini
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top